ArticleScientific reports2025
Added prognostic value of temporal muscle thickness in glioblastoma with age-stratified analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study.Therapeutic advances in endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To evaluate the prognostic value and age-stratified prognostic significance of temporal muscle thickness (TMT) in isocitrate dehydrogenase-wild type glioblastoma (GBM) based on the 2021 WHO central nervous system tumor classification. We retrospectively analyzed 285 patients with GBM treated between 2009 and 2022. Patients were subdivided into sarcopenic and non-sarcopenic groups based on the first quartile TMT value. Cox regression analysis was conducted to evaluate associations between overall survival (OS) and TMT, clinical characteristics, and molecular alteration status. Propensity score matching was conducted to control for the potential confounders. Age-stratified analyses of prognostic differences were conducted. In total, 285 patients (mean age = 59 years; standard deviation = 14; 242 males) were included. Multivariable Cox regression revealed that TMT was significantly associated with OS (Hazard ratio [HR], 1.42; 95% confidence interval (CI), 1.06-1.90; p = 0.02). Age (HR, 1.02; 95% CI, 1.01-1.03; p = 0.001), Karnofsky Performance Status (HR, 0.98; 95% CI, 0.97-0.99; p = 0.001), and mMGMT status (HR, 0.47; 95% CI, 0.35-0.63; p = 0.001) were also significantly associated with OS. In age- and sex-matched patients, TMT showed a significant association with OS (HR, 1.57; 95% CI, 1.09-2.28; p = 0.014). TMT inclusion in the multivariable Cox regression analysis model improved the concordance index from 0.685 to 0.706, with an age-dependent increase in its prognostic value (p = 0.01). TMT is an independent prognostic marker for OS in GBM, with its prognostic value increasing progressively with patient age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.